Rheumatology Advance Access originally published online on March 31, 2003
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Rheumatology 2003; 42: 617-621
© 2003 British Society for Rheumatology
Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-
therapy
Department of Rheumatology, University Hospital and
1 Department of Infectious Disease Control, University Hospital, Basel, Switzerland
Objective. With rising numbers of anti-tumour necrosis factor 
(TNF-) treatments for rheumatoid arthritis (RA), Crohn's disease and other conditions, physicians unaware of potential pitfalls are increasingly likely to encounter associated severe infections. Our purpose was to assess the incidence and nature of severe infections in our RA patients under anti-TNF- therapy.
Methods. We reviewed patient charts and records of the Infectious Disease Unit for serious infections in patients with RA in the 2 yr preceding anti-TNF- therapy and during therapy.
Results. Serious infections affected 18.3% of patients treated with infliximab or etanercept. The incidence was 0.181 per anti-TNF- treatment year vs 0.008 in the 2 yr preceding anti-TNF- therapy. In several cases, only a few signs or symptoms indicated the severity of developing infections, including sepsis.
Conclusions. A high level of suspicion of infection is necessary in patients under anti-TNF- therapy. We suggest additional strategies for the prevention, rapid identification and pre-emptive therapy of such infections.
KEY WORDS: TNF-, anti-TNF- therapy, Infection, Complications, Rheumatoid arthritis.
Correspondence to: P. Hasler, Rheumatologische Universitätsklinik, Felix Platter-Spital, Burgfelderstrasse 101, CH-4055 Basel, Switzerland. E-mail: paul.hasler{at}ksa.ch
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  C. C. Belizna, M. A. Hamidou, H. Levesque, L. Guillevin, and Y. Shoenfeld Infection and vasculitis Rheumatology, May 1, 2009; 48(5): 475 - 482. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Franklin, J. Greenspan, and S. Chen Anti-Tumor Necrosis Factor-alpha Therapy Provokes Latent Leishmaniasis in a Patient with Rheumatoid Arthritis Ann. Clin. Lab. Sci., January 1, 2009; 39(2): 192 - 195. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C Salliot, M Dougados, and L Gossec Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials Ann Rheum Dis, January 1, 2009; 68(1): 25 - 32. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Bernatsky, M. Hudson, and S. Suissa Anti-rheumatic drug use and risk of serious infections in rheumatoid arthritis Rheumatology, July 1, 2007; 46(7): 1157 - 1160. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Borras-Blasco, C. Nunez-Cornejo, A. Gracia-Perez, J D. Rosique-Robles, M. E. Castera, E. Viosca, and F J. Abad Parapharyngeal Abscess in a Patient Receiving Etanercept Ann. Pharmacother., February 1, 2007; 41(2): 341 - 344. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Gaffo, K. G. Saag, and J. R. Curtis Treatment of rheumatoid arthritis Am. J. Health Syst. Pharm., December 15, 2006; 63(24): 2451 - 2465. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M H Schiff, G R Burmester, J D Kent, A L Pangan, H Kupper, S B Fitzpatrick, and C Donovan Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis Ann Rheum Dis, July 1, 2006; 65(7): 889 - 894. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Bongartz, A. J. Sutton, M. J. Sweeting, I. Buchan, E. L. Matteson, and V. Montori Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA, May 17, 2006; 295(19): 2275 - 2285. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S Goode, G Tierney, and C Deighton Life threatening intra-abdominal sepsis in patients on anti-TNF-{alpha} therapy Gut, April 1, 2006; 55(4): 590 - 591. [Full Text] [PDF]
|
|
|
|
|
|
M. C. Kapetanovic, T. Saxne, A. Sjoholm, L. Truedsson, G. Jonsson, and P. Geborek Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis Rheumatology, January 1, 2006; 45(1): 106 - 111. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Uthman, A. Husari, Z. Touma, and S. S. Kanj Fatal streptococcal toxic shock syndrome in a patient with rheumatoid arthritis treated with etanercept Rheumatology, September 1, 2005; 44(9): 1200 - 1201. [Full Text] [PDF]
|
|
|
|
|
|
J. Torre-Cisneros, M. del Castillo, J. J. Caston, M. C. Castro, V. Perez, and E. Collantes Infliximab does not activate replication of lymphotropic herpesviruses in patients with refractory rheumatoid arthritis Rheumatology, September 1, 2005; 44(9): 1132 - 1135. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Marie, P. Heliot, F. Roussel, F. Herve, J. F. Muir, and H. Levesque Fatal Mycobacterium peregrinum pneumonia in refractory polymyositis treated with infliximab Rheumatology, September 1, 2005; 44(9): 1201 - 1202. [Full Text] [PDF]
|
|
|
|
 |
|
 G. Stratakos, I. Kalomenidis, V. Papas, K. Malagari, A. Kollintza, C. Roussos, M. Anagnostopoulou, O. Paniara, S. Zakynthinos, and S. A. Papiris Cough and fever in a female with Crohn's disease receiving infliximab Eur. Respir. J., August 1, 2005; 26(2): 354 - 357. [Full Text] [PDF]
|
|
|
|
 |
|
 G. Schett, P. Herak, W. Graninger, J. S. Smolen, and M. Aringer Listeria-Associated Arthritis in a Patient Undergoing Etanercept Therapy: Case Report and Review of the Literature J. Clin. Microbiol., May 1, 2005; 43(5): 2537 - 2541. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Chevillotte-Maillard, P. Ornetti, R. Mistrih, C. Sidot, J. Dupuis, J.-A. Dellas, C. Tavernier, and J. F. Maillefert Survival and safety of treatment with infliximab in the elderly population Rheumatology, May 1, 2005; 44(5): 695 - 696. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Rodriguez and J. A. Fishman Prevention of Infection Due to Pneumocystis spp. in Human Immunodeficiency Virus-Negative Immunocompromised Patients Clin. Microbiol. Rev., October 1, 2004; 17(4): 770 - 782. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Molloy, S. Ramakrishnan, E. Murphy, and M. Barry Morbidity and mortality in rheumatoid patients during treatment with adalimumab and infliximab Rheumatology, April 1, 2004; 43(4): 522 - 523. [Full Text] [PDF]
|
|
|
|
|
|
S. A. Wright and A. J. Taggart Pneumococcal vaccination for RA patients on TNF-{alpha} antagonists Rheumatology, April 1, 2004; 43(4): 523 - 523. [Full Text] [PDF]
|
|
|
|
|
|
C. Estrach, V. E. Abernethy, and J. K. Dawson Infections and anti-TNF therapy: strategies for screening based on clinical experience Rheumatology, January 1, 2004; 43(1): 115 - 116. [Full Text] [PDF]
|
|
|
|
|
|
P. D. W. Kiely Symptom concealment--a new phenomenon in patients treated with biological therapies? Rheumatology, January 1, 2004; 43(1): 114 - 115. [Full Text] [PDF]
|
|